

UnitedHealthcare Pharmacy
Clinical Pharmacy Programs

Program Number	2026 P 2391-1
Program	Prior Authorization/Medical Necessity
Medication	Redemplo® (plozasiran)
P&T Approval Date	2/2026
Effective Date	5/1/2026

1. Background:

Redemplo® is an apolipoprotein C-III (apoC-III)-directed small interfering ribonucleic acid (siRNA) indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS).

2. Coverage Criteria^a:

A. Initial Authorization

1. **Redemplo** will be approved based on **all** of the following criteria:

a. **Both** of the following:

(1) Diagnosis of familial chylomicronemia syndrome (FCS) (i.e., monogenic chylomicronemia, type 1 hyperlipoproteinemia)

-AND-

(2) Diagnosis has been confirmed by **both** of the following:

(a) **One** of the following:

i. Genetic confirmation of FCS (e.g., homozygous, compound heterozygous, or double heterozygote for loss-of-function or otherwise inactivating mutations in genes affecting lipoprotein lipase activity including *LPL*, *GPIHBP1*, *APOA5*, *APOC2*, or *LMF1*)

-OR-

ii. North American FCS (NAFCS) Score \geq 45

-AND-

(b) Untreated fasting triglyceride levels greater than or equal to 880 mg/dL

-AND-

b. Prescribed by **one** of the following:

(1) Cardiologist

- (2) Endocrinologist
- (3) Gastroenterologist
- (4) Lipid specialist (lipidologist)

-AND-

- c. Not used in combination with Tryngolza (olezarsen)

Authorization will be issued for 12 months

B. Reauthorization

1. **Redemplo** will be approved based on **all** of the following criteria:

- a. Documentation of positive clinical response to **Redemplo** therapy (e.g., reduction in triglycerides, reduction in episodes of acute pancreatitis)

-AND-

- b. Prescribed by **one** of the following:

- (1) Cardiologist
- (2) Endocrinologist
- (3) Gastroenterologist
- (4) Lipid specialist (lipidologist)

-AND-

- c. Not used in combination with Tryngolza (olezarsen)

Authorization will be issued for 12 months

^a State mandates may apply. Any federal regulatory requirements and the member specific benefit plan coverage may also impact coverage criteria. Other policies and utilization management programs may apply.

3. Additional Clinical Rules:

- Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic. Use of automated approval and re-approval processes varies by program and/or therapeutic class.

4. References:

1. Redemplo [package insert]. Pasadena, CA: Arrowhead Pharmaceuticals, Inc.; November 2025.
2. Watts GF, Rosenson RS, Hegele RA, et al. Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk. *N Engl J Med*. 2025;392(2):127-137. doi:10.1056/NEJMoa2409368
3. Hegele RA, Ahmad Z, Ashraf A, et al. Development and validation of clinical criteria to identify familial chylomicronemia syndrome (FCS) in North America. *J Clin Lipidol*. Published online November 12, 2024. doi:10.1016/j.jacl.2024.09.008

4. Javed F, Hegele RA, Garg A, et al. Familial chylomicronemia syndrome: An expert clinical review from the National Lipid Association. *J Clin Lipidol.* 2025;19(3):382-403.
doi:10.1016/j.jacl.2025.03.013
5. Saadatagah S, Larouche M, Naderian M, et al. Recognition and management of persistent chylomicronemia: A Joint Expert Clinical Consensus by the National Lipid Association and the American Society for Preventive Cardiology. *J Clin Lipidol.* 2025;19(4):723-736.
doi:10.1016/j.jacl.2025.03.012

Program	Prior Authorization/Medical Necessity - Redemplo® (plozasiran)
Change Control	
Date	Change
2/2026	New program.